HK Stock Market Move | HBM Holdings-B(02142) up more than 14% again, recently announced a share buyback plan, Kollenbota Tagori monoclonal antibody injection liquid launched.

HBM HOLDINGS-B (02142) rose by more than 14% again, with a cumulative increase of over 100% since December 17th. As of the time of writing, it has risen by 13.94%, to 2.37 Hong Kong dollars, with a transaction volume of 12.3475 million Hong Kong dollars. In terms of news, Hebo Medicine announced that, according to the general authorization for the repurchase of shares approved by the company's shareholders at the annual general meeting on June 6, 2024, and (if applicable) any general authorization for the repurchase of shares approved by the shareholders at any future general meetings of the company, they plan to repurchase company shares on the open market from time to time at a value not exceeding 40 million Hong Kong dollars. In addition, on December 31st, the latest announcement on the website of the China National Medical Products Administration showed that Kechow Pharma's Class 1 new drug Tagolimab Injection has been approved for listing. It is reported that in August 2018, Hebo Medicine reached a cooperation agreement with Kechow Pharma, obtaining the exclusive development, production, and commercialization license for Tagolimab, which was then in phase 2 clinical trials, globally (excluding the Greater China region). The potential value of this agreement exceeds 350 million US dollars, as well as sales royalties.